花园药业

Zhejiang Garden Pharmaceutical is a Chinese pharmaceutical manufacturing company specializing in the research, development, production, and commercialization of chemical preparations and traditional Chinese medicines. The company focuses primarily on chronic disease areas such as cardiovascular, neurological, and metabolic disorders. Its commercial portfolio includes key products like Valsartan/Amlodipine tablets, Doxofylline injections, Thioctic Acid injections, and the recently approved Upadacitinib sustained-release tablets and Ezetimibe/Atorvastatin Calcium tablets. Acquired by Zhejiang Garden Biopharmaceutical in 2021, the company operates as a wholly-owned subsidiary, leveraging an integrated 'API + finished drug' industrial chain.